drugset / Trial / NCT05544656
The Prognostic Value of Biomarkers and the Effect of Tolperisone in Acute Low Back Pain and Sciatic Pain "BETA"
Phase 3
Unknown
150 enrolled
Semmelweis University
MEDITOP Pharmaceutical LTD, Hungary · collabNational Research Develpment and Innovation Fund, Hungary · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of the trial is to identify biomarkers from the blood as well as electrophysiologic and morphometric features (chemical, electrophysiologic and ultrasound biomarkers) that reflect the intensity of pain and/or foretell the efficacy of pharmacological (non-surgical) treatment in patients with acute low back pain.
Timeline
- Start
- 2019-12-13
- Primary completion
- 2023-12-31
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tolperisone | Small molecule | 150 mg | — |
Indications
No indication recorded.